Nanri M, Yamamoto A, Matsuura N
Pharmacology Research Lab., Taiho Pharmaceutical Co. Ltd., Tokushima, Japan.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2000 May;20(2):45-50.
Piracetam [2-oxo-1-pyrrolidineacetamide], a cyclic GABA, has been used in Europe for the treatment of patients with cognitive disorders. We investigated the effect of piracetam on urea-induced myoclonus in rats. Myoclonus was induced by intraperitoneal injection of 4.5 g/kg urea, and was recorded with EMG and video apparatus. The incidence of induced myoclonus decreased significantly by intraperitoneal injection of 300 mg/kg piracetam and oral administration of 0.3-10 mg/kg clonazepam. Furthermore, the combined application of 100 mg/kg piracetam and 0.03-0.1 mg/kg clonazepam was effective in ameliorating the myoclonus, although separate administrations were not effective. These findings suggest that piracetam is an effective drug for treating myoclonus, particularly when it is used in combination with clonazepam.
吡拉西坦[2-氧代-1-吡咯烷乙酰胺],一种环状γ-氨基丁酸,在欧洲已被用于治疗认知障碍患者。我们研究了吡拉西坦对尿素诱导的大鼠肌阵挛的影响。通过腹腔注射4.5 g/kg尿素诱导肌阵挛,并用肌电图和视频设备进行记录。腹腔注射300 mg/kg吡拉西坦和口服0.3 - 10 mg/kg氯硝西泮可使诱导的肌阵挛发生率显著降低。此外,100 mg/kg吡拉西坦和0.03 - 0.1 mg/kg氯硝西泮联合应用对改善肌阵挛有效,尽管单独给药无效。这些发现表明吡拉西坦是治疗肌阵挛的有效药物,特别是与氯硝西泮联合使用时。